Genetic variation of interleukin-1 receptor type 1 is associated with severity of COVID-19 disease
- PMID: 34952040
- PMCID: PMC8690223
- DOI: 10.1016/j.jinf.2021.12.010
Genetic variation of interleukin-1 receptor type 1 is associated with severity of COVID-19 disease
Conflict of interest statement
Declaration of Competing Interest The authors have no potential conflicts of interest to disclose.
Comment on
-
Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: A comparative analysis.J Infect. 2020 Oct;81(4):e11-e17. doi: 10.1016/j.jinf.2020.07.008. Epub 2020 Jul 8. J Infect. 2020. PMID: 32652164 Free PMC article.
References
-
- Conti P., Caraffa A., Gallenga C.E., Ross R., Kritas S.K., Frydas I., et al. Coronavirus-19 (SARS-CoV-2) induces acute severe lung inflammation via IL-1 causing cytokine storm in COVID-19: a promising inhibitory strategy. J Biol Regul Homeost Agents. 2020;34(6):1971–1975. - PubMed
-
- Gabay C., Lamacchia C., Palmer G. IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol. 2010;6(4):232–241. - PubMed
-
- Dinarello C.A. The IL-1 family of cytokines and receptors in rheumatic diseases. Nat Rev Rheumatol. 2019;15(10):612–632. - PubMed
-
- Lawlor D.A., Harbord R.M., Sterne J.A., Timpson N., Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Stat Med. 2008;27(8):1133–1163. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical